On February 25, 2026, Bruker introduced CellScape XR, its next-generation spatial proteomics solution geared toward diagnostic and prognostic research. The rollout marks a strategic expansion of Bruker’s life sciences portfolio into high-resolution imaging mass spectrometry for clinical applications. CellScape XR integrates enhanced spatial resolution with advanced proteomic workflows to map protein distributions in tissue samples. The platform is positioned to accelerate biomarker discovery, streamline translational research, and support precision medicine initiatives in oncology and immunology.